|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
Telix Pharmaceuticals Ltd (Name of Issuer) |
Ordinary Shares (Title of Class of Securities) |
87961M105 (CUSIP Number) |
11/12/2024 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
| Rule 13d-1(c)
|
 Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | 87961M105 |
| 1 | Names of Reporting Persons
Kluge Andreas | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
GERMANY
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
22,675,000.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
6.78 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person: (1) Footnote to Row 11: Based on 334,683,357 ordinary shares outstanding as of September 30, 2024, as reported in the Form 20-F filed by the Issuer with the Securities and Exchange Commission on October 17, 2024.
SCHEDULE 13G
|
| CUSIP No. | 87961M105 |
| 1 | Names of Reporting Persons
Gnosis Verwaltungsgesellschaft m.b.H. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
GERMANY
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
22,675,000.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
6.78 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person: (1) Footnote to Row 11: Based on 334,683,357 ordinary shares outstanding as of September 30, 2024, as reported in the Form 20-F filed by the Issuer with the Securities and Exchange Commission on October 17, 2024.
SCHEDULE 13G
|
| Item 1. | ||
| (a) | Name of issuer:
Telix Pharmaceuticals Ltd | |
| (b) | Address of issuer's principal executive offices:
55 Flemington Road, North Melbourne, Victoria, Australia, 3051 | |
| Item 2. | ||
| (a) | Name of person filing:
Dr. Andreas Kluge and Gnosis Verwaltungsgesellschaft m.b.H. (the "Reporting Persons") | |
| (b) | Address or principal business office or, if none, residence:
Dr. Andreas Kluge
Veilchenweg 38, 01326 Dresden, Germany
Gnosis Verwaltungsgesellschaft m.b.H.
Veilchenweg 38, 01326 Dresden, Germany | |
| (c) | Citizenship:
Dr. Andreas Kluge
Germany
Gnosis Verwaltungsgesellschaft m.b.H.
Organized under the laws of Germany | |
| (d) | Title of class of securities:
Ordinary Shares | |
| (e) | CUSIP No.:
87961M105 | |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| (a) | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
| |
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
| |
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
| |
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
| |
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
| |
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
| |
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
| |
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
| |
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
| |
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: | |
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
| |
| Item 4. | Ownership | |
| (a) | Amount beneficially owned:
The ownership information below represents beneficial ownership of ordinary shares by the Reporting Persons as of November 12, 2024, based upon 334,683,357 ordinary shares of the Issuer outstanding as of September 30, 2024.
Dr. Andreas Kluge is the Managing Director of Gnosis Verwaltungsgesellschaft m.b.H. ("Gnosis") and has discretionary authority to vote and dispose of 22,675,000 ordinary shares held by Gnosis.
Dr. Andreas Kluge
22,675,000 ordinary shares
Gnosis Verwaltungsgesellschaft m.b.H.
22,675,000 ordinary shares | |
| (b) | Percent of class:
Dr. Andreas Kluge
6.78%
Gnosis Verwaltungsgesellschaft m.b.H.
6.78 %
| |
| (c) | Number of shares as to which the person has:
| |
| (i) Sole power to vote or to direct the vote:
Dr. Andreas Kluge
0
Gnosis Verwaltungsgesellschaft m.b.H.
0 | ||
| (ii) Shared power to vote or to direct the vote:
Dr. Andreas Kluge
22,675,000
Gnosis Verwaltungsgesellschaft m.b.H.
22,675,000 | ||
| (iii) Sole power to dispose or to direct the disposition of:
Dr. Andreas Kluge
0
Gnosis Verwaltungsgesellschaft m.b.H.
0 | ||
| (iv) Shared power to dispose or to direct the disposition of:
Dr. Andreas Kluge
22,675,000
Gnosis Verwaltungsgesellschaft m.b.H.
22,675,000 | ||
| Item 5. | Ownership of 5 Percent or Less of a Class. | |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
| Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
| Item 9. | Notice of Dissolution of Group. | |
Not Applicable
| ||
| Item 10. | Certifications: |
Not Applicable
|
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|